11C-Choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer

Clinical Nuclear Medicine

Volumn 40, Issue 5, 2015, Pages e265-e270

  Ceci, Francesco ^a,b   Castellucci, Paolo ^a   Graziani, Tiziano ^a   Schiavina, Riccardo ^a   Chondrogiannis, Sotirios ^c   Bonfiglioli, Rachele ^a   Costa, Stefano ^a   Virgolini, Irene J ^b   Rubello, Domenico ^c   Fanti, Stefano ^a   Colletti, Patrick M ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d LAC USC MEDICAL CENTER   (United States)

Author keywords

11C choline PET CT; bone metastasis; osteoblastic bone lesions; osteolytic bone lesions; recurrent prostate cancer

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID; CARBON; CHOLINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE METASTASIS; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOBLAST; OSTEOLYSIS; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; BONE TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; SCINTISCANNING; SECONDARY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928395270     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000783     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Ferlay J, Bray F, Pisani P, GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide Version 1.0. IARC CancerBase No. 5. Lyon, France: IARC Press; 2000.
3. Thobe MN, Clark RJ, Bainer RO, From prostate to bone: key players in prostate cancer bone metastasis. Cancers (Basel). 2011; 3: 478-493.
4. Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
5. Coleman RE,. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27: 165-176.
6. Bubendorf L, Schopfer A, Wagner U, Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000; 31: 578-583.
7. Bogdanos J, Karamanolakis D, Tenta R, Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer. 2003; 10: 279-289.
8. Coleman RE,. Skeletal complications of malignancy. Cancer. 1997; 80: 1588-1594.
9. Lu Y, Cai Z, Xiao G, Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res. 2007; 67: 3646-3653.
10. Keller ET, Zhang J, Cooper CR, Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 2001; 20: 333-349.
11. Messiou C, Cook G, de Souza NM,. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer. 2009; 101: 1225-1232.
12. Mundy GR,. Mechanisms of osteolytic bone destruction. Bone. 1991; 12: S1-S6.
13. Berruti A, Piovesan A, Torta M, Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer. 1996; 73: 1581-1587.
14. Jung K, Lein M, Stephan C, Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004; 111: 783-791.
15. Clarke NW, McClure J, George NJ,. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991; 68: 74-80.
16. Corey E, Brown LG, Kiefer JA, Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005; 65: 1710-1718.
17. Keller ET, Brown J,. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004; 91: 718-729.
18. Weilbaecher KN, Guise TA, McCauley LK,. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011; 11: 411-425.
19. 11C-Choline PET/CT scan before salvage radiation therapy? J Nucl Med. 2014; 55: 1424-1429.
20. 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009; 50: 1394-1400.
21. Choueiri TK, Dreicer R, Paciorek A, A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008; 179: 906-910.
22. 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012; 81: e893-e896.
23. 11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012; 39: 13-26.
24. Krause BJ, Souvatzoglou M, Tincel M, The detection rate of 11-C choline PET/TC depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35: 18-23.
25. Giovacchini G, Picchio M, Scattoni V, Doubling time for prediction of [(11)C]choline PET/ CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010; 37: 1106-1116.
26. 11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging. 2014; 41: 878-886.
27. Khan MA, Carter HB, Epstein JI, Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003; 170: 2274-2278.
28. 11C] choline. J Labelled Comp Radiopharm. 2000; 49: 195-203.
29. Beheshti M, Vali R, Waldenberger P, The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010; 12: 98-107.
30. Ceci F, Castellucci P, Mamede M, (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2013; 40: 149-155.
31. Saad F, Clarke N, Colombel M,. Natural history and treatment of bone complications in prostate cancer. Eur Urol. 2006; 49: 429-440.
32. Rafiei S, Komarova SV,. Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells. BMC Cancer. 2013; 13: 605.
33. Sottnik JL, Keller ET,. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med. 2013; 13: 626-639.
34. Castellano D, Sepulveda JM, Garcia-Escobar I, The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011; 16: 136-145.
35. Zhang J, Dai J, Qi Y, Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 2001; 107: 1235-1244.
36. Whyte MP, Mumm S,. Heritable disorders of the RANKL/OPG/RANK signaling pathway. J Musculoskelet Neuronal Interact. 2004; 4: 254-267.
37. Fizazi K, Carducci M, Smith M, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377: 813-822.
38. Lipton A, Goessl C,. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone. 2011; 48: 96-99.
39. Henry DH, Costa L, Goldwasser F, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29: 1125-1132.
40. Weintraub B,. Trials define anti-tumor effects of anti-resorptive agents: denosumab ahead of zoledronate 2 to 1. BioDrugs. 2011; 25: 135-138.
41. Mirels H,. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res. 2003;(Suppl 415): S4-S13.
42. Muhammad UJ, Scully SP,. In brief: classifications in brief: Mirels' classification: metastatic disease in long bones and impending pathologic fracture. Clin Orthop Relat Res. 2010; 468: 2825-2827.
43. Langsteger W, Haim S, Knauer M, Imaging of bone metastases in prostate cancer: an update. Q J Nucl Med Mol Imaging. 2012; 56: 447-458.
44. Cheville JC, Tindall D, Boelter C, Metastatic prostate carcinoma to bone. Cancer. 2002; 95: 1028-1036.
45. Carlin BI, Andriole GL,. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000; 88: 2989-2994.